The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of depression, officials said. The FDA granted approval to Spravato (esketamine ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The US Food and Drug Administration’s (FDA’s) decision makes Spravato the first-ever standalone treatment for adults with ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Approval of Spravato, granted following FDA priority review, was based on the results of a randomized, double-blind, ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).